Glycinebetaine

Glycinebetaine

SCHEMBL3095441

CC(=O)O.C[N+](C)(C)CC(=O)[O-].N

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

BHMTBHMT2

The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
APEX1 P27695 1/20 0.48
SLC22A16 Q86VW1 1/20 0.39
FFAR3 O14843 2/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
CPT2 P23786 1/20 0.37
CPT1A P50416 1/20 0.37
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
HRH1 P35367 1/20 0.36
KMT2A Q03164 1/20 0.36
CRAT P43155 1/20 0.36
CA1 P00915 2/20 0.35
BBOX1 O75936 6/20 0.34
ACHE P22303 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycinebetaine SCHEMBL604825 0.97 TSHR (0.52) TSHRALDH1A1LMNAAPEX1SLC22A16
Glycinebetaine SCHEMBL132824 0.92
Glycinebetaine SCHEMBL7753166 0.90 TSHR (0.46) TSHRALDH1A1LMNAAPEX1SLC22A16
Glycinebetaine SCHEMBL9281697 0.89 TSHR (0.55) TSHRALDH1A1LMNAAPEX1SLC22A16
Glycinebetaine SCHEMBL2803780 0.89 TSHR (0.53) TSHRALDH1A1LMNAAPEX1SLC22A16
Glycinebetaine SCHEMBL7739 0.89
Betaine SCHEMBL31467313 0.89
Glycinebetaine SCHEMBL8678519 0.89 TSHR (0.53) TSHRALDH1A1LMNAAPEX1SLC22A16
Glycinebetaine SCHEMBL4900209 0.89
Glycinebetaine SCHEMBL11906100 0.87 TSHR (0.48) TSHRALDH1A1LMNAAPEX1SLC22A16

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100233444-A1 Composition,article, its manufacture and use IMAGICHEM LIMITED (GB) 2010-09-16 US disclosed
EP-2035231-A2 COMPOSITION, ARTICLE, ITS MANUFACTURE AND USE Imagichem Limited (GB) 2009-03-18 EP disclosed
WO-2008001127-A2 COMPOSITION, ARTICLE, ITS MANUFACTURE AND USE IMAGICHEM LIMITED (GB) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100233444-A1 Composition,article, its manufacture and use DSTN, ING2, IGF1R TSHR 2853/4885ALDH1A1 4438/4885LMNA 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.